星空体育官方入口网站网址大全-登录入口官网

#艾伯维#

43篇内容 | 1867人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350235, encodeId=f2511350235fb, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, objectType=article, longId=723787, objectId=0b3be23787cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3be23787cf, replyNumber=0, likeNumber=59, createdTime=2022-04-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3be23787cf, moduleTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0b3be23787cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350234, encodeId=6fa9135023450, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=梅栏访 | 对话艾伯维中国总经理欧思朗：好的创新是不设限, objectType=article, longId=724716, objectId=8491e24716ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8491e24716ab, replyNumber=0, likeNumber=73, createdTime=2022-03-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8491e24716ab, moduleTitle=梅栏访 | 对话艾伯维中国总经理欧思朗：好的创新是不设限, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8491e24716ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350233, encodeId=527a135023308, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维指控Alvotech窃取修美乐商业机密, objectType=article, longId=209489, objectId=a3022094894b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3022094894b, replyNumber=0, likeNumber=60, createdTime=2021-04-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3022094894b, moduleTitle=艾伯维指控Alvotech窃取修美乐商业机密, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a3022094894b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350232, encodeId=5f661350232ef, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=蛋白降解剂成大热门！艾伯维宣布超10亿美元合作，这次目标是癌症和免疫疾病, objectType=article, longId=204301, objectId=4c842043019d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c842043019d, replyNumber=0, likeNumber=56, createdTime=2020-12-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c842043019d, moduleTitle=蛋白降解剂成大热门！艾伯维宣布超10亿美元合作，这次目标是癌症和免疫疾病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4c842043019d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350231, encodeId=da32135023144, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=CD37：艾伯维/Genmab合作的重要靶点, objectType=article, longId=201983, objectId=91e0201983b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91e0201983b1, replyNumber=0, likeNumber=58, createdTime=2020-10-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91e0201983b1, moduleTitle=CD37：艾伯维/Genmab合作的重要靶点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=91e0201983b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350230, encodeId=3873135023049, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47, objectType=article, longId=200312, objectId=3baf200312d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3baf200312d2, replyNumber=0, likeNumber=0, createdTime=2020-09-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3baf200312d2, moduleTitle=高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3baf200312d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350229, encodeId=17e01350229e2, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=61, createdTime=2020-06-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350228, encodeId=8d4a135022838, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, objectType=article, longId=195642, objectId=43db195642e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db195642e7, replyNumber=0, likeNumber=66, createdTime=2020-06-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db195642e7, moduleTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43db195642e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350227, encodeId=ee40135022e3b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维已完成对艾尔建的全部收购，强大的在研产品组合助力长期可持续增长, objectType=article, longId=193847, objectId=4fb819384e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fb819384e69, replyNumber=0, likeNumber=69, createdTime=2020-05-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fb819384e69, moduleTitle=艾伯维已完成对艾尔建的全部收购，强大的在研产品组合助力长期可持续增长, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4fb819384e69)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350226, encodeId=9f271350226ef, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=75, createdTime=2020-01-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350225, encodeId=8550135022547, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, objectType=article, longId=185935, objectId=6a1818593535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1818593535, replyNumber=0, likeNumber=0, createdTime=2020-01-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1818593535, moduleTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6a1818593535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350224, encodeId=86701350224c1, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, objectType=article, longId=185034, objectId=d32d1850343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d32d1850343b, replyNumber=0, likeNumber=72, createdTime=2019-12-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d32d1850343b, moduleTitle=艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d32d1850343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350223, encodeId=eed6135022367, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, objectType=article, longId=184955, objectId=41c3184955ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c3184955ce, replyNumber=0, likeNumber=58, createdTime=2019-12-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c3184955ce, moduleTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=41c3184955ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350222, encodeId=c4671350222c3, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, objectType=article, longId=178087, objectId=e5861e8087e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5861e8087e1, replyNumber=0, likeNumber=53, createdTime=2019-08-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5861e8087e1, moduleTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e5861e8087e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350221, encodeId=a06b1350221a8, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=56, createdTime=2019-07-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350220, encodeId=47df1350220a2, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=重磅突发！艾伯维630亿美元收购艾尔建, objectType=article, longId=172195, objectId=b48a1e21957d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b48a1e21957d, replyNumber=0, likeNumber=67, createdTime=2019-06-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b48a1e21957d, moduleTitle=重磅突发！艾伯维630亿美元收购艾尔建, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b48a1e21957d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350219, encodeId=0a5f13502197d, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret, objectType=article, longId=165452, objectId=7fcf1654522f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fcf1654522f, replyNumber=0, likeNumber=60, createdTime=2019-05-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fcf1654522f, moduleTitle=美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7fcf1654522f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350218, encodeId=049c13502188d, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=58亿美元的收购"打水漂"了？艾伯维宣布裁员近200人, objectType=article, longId=163258, objectId=239716325867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=239716325867, replyNumber=0, likeNumber=53, createdTime=2019-03-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=239716325867, moduleTitle=58亿美元的收购"打水漂"了？艾伯维宣布裁员近200人, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=239716325867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350217, encodeId=dc5b135021ed2, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=全球首批！艾伯维银屑病新药在日本上市, objectType=article, longId=163083, objectId=b22316308396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22316308396, replyNumber=0, likeNumber=55, createdTime=2019-03-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22316308396, moduleTitle=全球首批！艾伯维银屑病新药在日本上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b22316308396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350216, encodeId=fe8413502168b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira, objectType=article, longId=134758, objectId=7a56134e586f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a56134e586f, replyNumber=0, likeNumber=51, createdTime=2018-04-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a56134e586f, moduleTitle=艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7a56134e586f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

艾伯维

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路

2022-04-09

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

梅栏访 | 对话艾伯维中国总经理欧思朗：好的创新是不设限

2022-03-20

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维指控Alvotech窃取修美乐商业机密

2021-04-05

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

蛋白降解剂成大热门！艾伯维宣布超10亿美元合作，这次目标是癌症和免疫疾病

2020-12-09

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

CD37：艾伯维/Genmab合作的重要靶点

2020-10-13

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

高瓴牵头砸进4亿美金，加持天境生物联手艾伯维开发明星靶点CD47

2020-09-07

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2020-06-22

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元

2020-06-12

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维已完成对艾尔建的全部收购，强大的在研产品组合助力长期可持续增长

2020-05-11

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-01-18

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎

2020-01-10

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维的JAK抑制剂Rinvoq，获得欧盟批准治疗类风湿性关节炎

2019-12-23

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

2019-12-21

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！

2019-08-23

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2019-07-15

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

重磅突发！艾伯维630亿美元收购艾尔建

2019-06-27

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret

2019-05-07

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

58亿美元的收购"打水漂"了？艾伯维宣布裁员近200人

2019-03-31

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

全球首批！艾伯维银屑病新药在日本上市

2019-03-29

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira

2018-04-12

科室
- - 订阅+
  - 更多科室
工具
服务